Yusuke Tachibana
Overview
Explore the profile of Yusuke Tachibana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tachibana Y, Morimoto K, Yamada T, Kawachi H, Tamiya M, Negi Y, et al.
Invest New Drugs
. 2024 Aug;
42(5):538-546.
PMID: 39168900
The association between depth of response (DpR) and treatment outcomes has been documented across various types of cancer. Immune checkpoint inhibitor (ICI)-based treatment is globally used as first-line treatment for...
2.
Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, et al.
Cancer Lett
. 2024 Jul;
598:217124.
PMID: 39059573
We previously reported that combined therapy with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and AXL inhibitor ONO-7475 is effective in preventing the survival of drug-tolerant cells in...
3.
Matsui Y, Yamada T, Katayama Y, Hirai S, Sawada R, Tachibana Y, et al.
Cancer Sci
. 2024 Jul;
115(10):3333-3345.
PMID: 39039802
Lazertinib, a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), demonstrates marked efficacy in EGFR-mutant lung cancer. However, resistance commonly develops, prompting consideration of therapeutic strategies to overcome...
4.
Ishida M, Iwasaku M, Doi T, Ishikawa T, Tachibana Y, Sawada R, et al.
Cancer Sci
. 2024 Mar;
115(5):1656-1664.
PMID: 38450844
Driver oncogenes are investigated upfront at diagnosis using multi-CDx systems with next-generation sequencing techniques or multiplex reverse-transcriptase polymerase chain reaction assays. Additionally, from 2019, comprehensive genomic profiling (CGP) assays have...
5.
Morimoto K, Yamada T, Hirai S, Katayama Y, Fukui S, Sawada R, et al.
Cancer Lett
. 2024 Feb;
587:216692.
PMID: 38342232
Recently, novel Kirsten rat sarcoma viral oncogene homolog (KRAS) inhibitors have been clinically developed to treat KRAS G12C-mutated non-small cell lung cancer (NSCLC) patients. However, achieving complete tumor remission is...
6.
Tachibana Y, Takayama K
Gan To Kagaku Ryoho
. 2023 Aug;
50(8):873-877.
PMID: 37608411
No abstract available.
7.
Tachibana Y, Yamada T, Tsuji T, Murai J, Takayama K
Cureus
. 2023 Jun;
15(5):e39499.
PMID: 37362462
It is recommended to get the multiple coronavirus disease 2019 (COVID-19) vaccinations for almost all people including asthma patients. A 70-year-old Japanese woman with asthma experienced worsening of respiratory symptoms...
8.
Hata T, Sakaguchi C, Hirano K, Kobe H, Ishida M, Nakano T, et al.
Thorac Cancer
. 2023 Mar;
14(11):1004-1011.
PMID: 36866788
Background: Patients with epidermal growth factor receptor (EGFR)-mutated, advanced non-small cell lung cancer have received immunochemotherapy as one of the treatment options after tyrosine kinase inhibitor (TKI) failure. Methods: We...
9.
Hata T, Sakaguchi C, Hirano K, Kobe H, Ishida M, Nakano T, et al.
J Cancer Res Clin Oncol
. 2022 Jun;
149(6):2475-2482.
PMID: 35737092
Purpose: The effect of immuno-chemotherapy on patients with advanced non-small-cell lung cancer (NSCLC) harboring oncogenic mutations remains poorly understood. This study aimed to characterize the efficacy of immuno-chemotherapy and determine...
10.
Tanaka S, Uchino J, Yokoi T, Kijima T, Goto Y, Suga Y, et al.
Diagnostics (Basel)
. 2022 Feb;
12(2).
PMID: 35204513
Combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapies (chemoimmunotherapy) is associated with significantly better survival outcomes than cytotoxic chemotherapies alone in patients with advanced non-small cell lung cancer (NSCLC)....